High clinical sensitivity and longitudinal monitoring of KRAS mutations across multiple cancer types demonstrated in urine

Ultra-high sensitivity drives clinical applications and pharmacodynamic monitoring in late-stage cancer patients

Agreement expands in-network health benefit access to Trovagene's Precision Cancer Monitoring platform for an additional 68 million covered lives

FedMed brings in-network health plan access to an additional 40 million covered lives

Agreement provides in-network coverage for 22 million individuals

Stifel 2015 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum

Interim results from a colorectal cancer study adds to the body of clinical evidence supporting Trovagene's urinary ctDNA platform for the detection and monitoring of actionable oncogene mutations using a non-invasive sample

Data for the detection and monitoring of EGFR T790M mutations to be presented at the AACR-NCI-EORTC International Conference

Consistent with prior clinical study results, non-invasive laboratory test is effective in determining mutational status

Quantitative detection and monitoring of circulating tumor DNA (ctDNA) and driver mutations can be used to rapidly detect treatment response

Data presented at the 30th International Papillomavirus Conference; general population screening trial is ongoing

Trovagene Research Institute aims to improve cancer care through advanced genomic solutions with the mission of accelerating adoption of Trovagene's Precision Cancer Monitoring platform in translational research and clinical applications

Clinical Data to be Presented in Oral Session on Liquid Biopsies at the 16th World Conference on Lung Cancer

Clinical data in lung, colorectal, and pancreatic cancer demonstrate the utility of Trovagene's Precision Cancer Monitoring platform as an important disease management tool

Study objective is to deliver a urinary liquid biopsy-based solution to provide faster and more accurate information for measuring response to immunotherapy

Data support the clinical utility of using the Company's Precision Cancer Monitoring technology in the management of non-small cell lung and colorectal cancers

Expanded physician access program, new awareness campaign, and clinical data presentations at ASCO highlight the Company's urine-based liquid biopsy service

Precision Cancer Monitoring technology offers advantages over tissue biopsy and demonstrates ability to monitor tumor dynamics in lung, pancreatic, and colon cancers

Company moves three EGFR mutation assays into its CLIA lab, expands clinical study programs in lung cancer, and prepares to deploy commercial strategy and sales team ahead of ASCO

Analysis concludes that use of Trovagene's urinary liquid biopsy significantly reduces costs when compared to tissue biopsy

Presentation to include results from PREDICTORS 4 study showing high sensitivity and potential for non-invasive test to be made available to millions of women who are unscreened for cervical cancer risk

Company's liquid biopsy technology features single molecule sensitivity and the ability to obtain significantly more circulating tumor DNA (ctDNA) from urine samples vs. plasma

Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imaging

Industry leader with strong track record for commercializing disruptive life science and diagnostic technologies, and leveraging innovative applications of next-generation sequencing

Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care

Large-scale study shows potential for non-invasive test to be made available to millions of women worldwide who are unscreened for the detection of cervical cancer